In summary, a small proportion of COVID-19 patients may have anti-PF4/X antibodies, only a fraction of which can be identified as anti-PF4/H antibodies, with the remainder representing antibodies against PF4, potentially in complex with an as yet unknown ‘anionic species’ (‘X’) [20,21,22]. Here, PF4 is linked to COVID-19.